[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100640739","diagnostic-value-of-68ga-pentixafor-petct-in-adrenal-tumors-with-aldosterone-and-cortisol-cosecretion-100640739",false,"NCT07605156","Diagnostic Value of 68Ga-Pentixafor PET\u002FCT in Adrenal Tumors With Aldosterone and Cortisol Cosecretion","Inclusion Criteria:\n\n* Age 18-80 years.\n\nConfirmed diagnosis of PA+MACS according to guideline-directed algorithms: elevated aldosterone-to-renin ratio (ARR) and at least one positive confirmatory test for primary aldosteronism, together with serum cortisol \\>1.8 µg\u002FdL (\\>50 nmol\u002FL) after a 1 mg overnight dexamethasone suppression test (1 mg-ONDST).\n\nScheduled to undergo \\[⁶⁸Ga\\]Pentixafor-CXCR4 PET\u002FCT imaging.\n\nMeeting surgical indications, scheduled for adrenalectomy or adrenal ablation, having provided written informed consent, and agreeing to a follow-up of at least 12 months.\n\nExclusion Criteria:\n\n* Previous adrenal surgery or confirmed adrenal malignancy.\n\nPregnancy or lactation.\n\nSevere renal impairment (eGFR \\\u003C30 mL·min-¹·1.73 m-²) or contraindication to contrast agents\u002Fradiopharmaceuticals.\n\nInability to discontinue medications that interfere with diagnostic testing according to protocol, or presence of severe infection\u002Funstable comorbidities that preclude relevant examinations.\n\nDefinite overt Cushing's syndrome (CS).\n\nCritical missing data, inability to complete the required examinations, or anticipated inability to attend follow-up.","ALL","18 Years","80 Years",{"count":19,"type":20},130,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to evaluate the diagnostic accuracy of 68 68\n\nGa-Pentixafor-CXCR4 PET\u002FCT in identifying the dominant side of hormone excess in adult patients (aged 18-80 years) with primary aldosteronism and concomitant mild autonomous cortisol secretion (PA+MACS) who are candidates for unilateral adrenalectomy or ablation. The main questions it aims to answer are:\n\nWhat is the overall diagnostic performance of 68 68 Ga-Pentixafor-CXCR4 PET\u002FCT for lateralizing the dominant source of aldosterone and cortisol co-secretion, as measured by the area under the receiver operating characteristic curve (AUC)?\n\nHow do the PET\u002FCT-based lateralization results compare with adrenal venous sampling (AVS) and metanephrine-corrected AVS, and are there clinical or biochemical factors that predict discordance between these methods?\n\nResearchers will compare the dominant side determined by PET\u002FCT with the reference standard derived from postoperative PASO outcomes and cortisol-related hormonal outcomes (supplemented by histopathology) to assess sensitivity, specificity, accuracy, and agreement. They will further compare PET\u002FCT results to conventional AVS and metanephrine-corrected AVS to determine concordance and identify potential predictors of discordant cases.\n\nParticipants will:\n\nProvide written informed consent and undergo baseline clinical, biochemical, and imaging assessments as part of routine PA+MACS work-up.\n\nUndergo a single 68 68 Ga-Pentixafor-CXCR4 PET\u002FCT scan, along with AVS and metanephrine-corrected AVS, typically within a 4-week window.\n\nBe discussed by a multidisciplinary team that integrates all diagnostic information to formulate an individualized surgical plan.\n\nIf surgery proceeds, be followed at 1, 3, 6, and 12 months postoperatively to assess blood pressure, antihypertensive medication use, serum potassium, aldosterone\u002Frenin\u002Fcortisol levels, and 1-mg overnight dexamethasone suppression test results.",[25],"Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion","RECRUITING","2026-05-17",{"date":29,"type":30},"2026-05-22","ACTUAL",{"date":32,"type":30},"2025-12-01",{"date":34,"type":20},"2027-09-30",{"name":36,"class":37},"Peking University First Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100564962","accuracy-of-68ga-pentixafor-petct-for-subtypting-diagnosis-in-patients-with-primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion-100564962","NCT06635993","Accuracy of 68Ga-Pentixafor PET\u002FCT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion","ABOARD","Inclusion Criteria:\n\n1. Getting the written informed consent\n2. The clear diagnosis of primary aldosteronism；\n3. Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol\u002Fl；\n4. Patients who are willing to undergo surgery；\n5. Adrenal CT or MRI scan of the adrenal glands with nodule (≥1cm).\n\nExclusion Criteria:\n\n1. PA patients who meet the by-passing AVS criteria \\[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \\>300pg\u002Fml\\]；\n2. Suspicion of familial hyperaldosteronism or Liddle syndrome. \\[i.e., age \\<20 years, hypertension and hypokalemia, or with family history\\]；\n3. Suspicion of pheochromocytoma or adrenal carcinoma；\n4. Patients with actively malignant tumor；\n5. Patients who have adrenalectomy history；\n6. Long-term use of glucocorticoids；\n7. Patients who are allergic to contrast media and cannot tolerate AVS；\n8. Pregnant or lactating women; with alcohol or drug abuse and mental disorders；\n9. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\\<60g\u002FL); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\<30 ml\u002Fmin\u002F1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol\u002FL); Obesity (BMI≥35 kg\u002Fm²); Untreated aneurysm; Other comorbidity potentially interfering with treatment；\n10. Consider patients with bilateral cortisol hypersecretion such as PBMAH or PPNAD.",{"count":47,"type":20},97,"6 Months","To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and\u002For postoperative remission as the reference standard for classification diagnosis.",[25],[52,53,54,55],"primary aldosteronism","autonomous cortisol secretion","Adrenal venous sampling","68Ga-Pentixafor PET\u002FCT","2024-10-09",{"date":58,"type":30},"2024-10-10",{"date":60,"type":30},"2024-08-12",{"date":62,"type":20},"2027-08-12",{"name":64,"class":37},"Qifu Li"]